Study details
Enrolling now
TAS-102 Trial
M.D. Anderson Cancer Center
NCT IDNCT05343013ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
25
Study length
about 4.9 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing TAS-102, a medication, to measure ctDNA levels in colorectal cancer patients after 6 months of treatment. The goal is to determine the amount of ctDNA present in the blood.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take TAS-102
PhasePhase 2
Primary goalTo determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.
Body systems
Oncology